drugset / Trial / NCT02958163
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
Phase 2
Terminated
3 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Centre Hospitalier Universitaire UCLouvain Namur · collabClinique Saint Joseph, Liège · collabErasme University Hospital · collabJules Bordet Institute · collabUniversity of Liege · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone versus DEB-TACE followed by Stereotactic Ablative Radiotherapy (SABR) in patients with hepatocarcinoma stage BCLC B. This trial will also include one substudy. This substudy will confront the immuno-histochemical results collected on tumoral biopsies to the biological and imaging (MRI) results. Every patient participating to the trial can also participate to this substudy.
Timeline
- Start
- 2017-02-20
- Primary completion
- 2017-10-17
- Completion
- 2017-10-17
Outcome
Outcome not reported
Stopped (Enrollment): “lack of recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Doxorubicin | Other / unclassified | — | — |